

PHARMACEUTICAL 2022

CytoDyn Inc. Rank 421 of 466









PHARMACEUTICAL 2022

CytoDyn Inc. Rank 421 of 466



The relative strengths and weaknesses of CytoDyn Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytoDyn Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 11% points. The greatest weakness of CytoDyn Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is -134%, being 212% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	129,581
Cost of Goods Sold	0
Intangible Assets	1,653
Liabilities, Current	152,546
Liabilities, Non-Current	552
Other Assets	712
Other Compr. Net Income	0
Other Expenses	31,402
Other Liabilities	0
Other Net Income	-30,522
Other Revenues	0
Property and Equipment	134
Research and Development	58,430
Selling, General and Administrative Expense	34,320

Output Variable	Value in 1000 USD
Assets	132,080
Liabilities	153,098
Expenses	124,152
Revenues	0
Stockholders Equity	-21,018
Net Income	-154,674
Comprehensive Net Income	-154,674
Economic Capital Ratio	-134%

